Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms defined by the presence of cells with secretory granules and the potential to produce and release high levels of vasoactive peptides into the circulation, leading to severe flushing and diarrhea, which may adversely affect quality of...

Descripción completa

Detalles Bibliográficos
Autores principales: Carter, Corey A., Degesys, Aiste, Oronsky, Bryan, Scicinski, Jan, Caroen, Scott Z., Oronsky, Arnold L., Reid, Tony, Cabrales, Pedro, Roswarski, Joe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2015
Materias:
Published online: October 2015
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649750/
https://www.ncbi.nlm.nih.gov/pubmed/26600780
http://dx.doi.org/10.1159/000441775
_version_ 1782401410054225920
author Carter, Corey A.
Degesys, Aiste
Oronsky, Bryan
Scicinski, Jan
Caroen, Scott Z.
Oronsky, Arnold L.
Reid, Tony
Cabrales, Pedro
Roswarski, Joe
author_facet Carter, Corey A.
Degesys, Aiste
Oronsky, Bryan
Scicinski, Jan
Caroen, Scott Z.
Oronsky, Arnold L.
Reid, Tony
Cabrales, Pedro
Roswarski, Joe
author_sort Carter, Corey A.
collection PubMed
description Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms defined by the presence of cells with secretory granules and the potential to produce and release high levels of vasoactive peptides into the circulation, leading to severe flushing and diarrhea, which may adversely affect quality of life. This report presents the case of a 64-year-old man with chronic refractory diarrhea due to pulmonary NET treated with the experimental anticancer agent RRx-001 in a phase II trial called TRIPLE THREAT with subsequent resolution of his diarrhea.
format Online
Article
Text
id pubmed-4649750
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-46497502015-11-23 Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor Carter, Corey A. Degesys, Aiste Oronsky, Bryan Scicinski, Jan Caroen, Scott Z. Oronsky, Arnold L. Reid, Tony Cabrales, Pedro Roswarski, Joe Case Rep Oncol Published online: October 2015 Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms defined by the presence of cells with secretory granules and the potential to produce and release high levels of vasoactive peptides into the circulation, leading to severe flushing and diarrhea, which may adversely affect quality of life. This report presents the case of a 64-year-old man with chronic refractory diarrhea due to pulmonary NET treated with the experimental anticancer agent RRx-001 in a phase II trial called TRIPLE THREAT with subsequent resolution of his diarrhea. S. Karger AG 2015-10-30 /pmc/articles/PMC4649750/ /pubmed/26600780 http://dx.doi.org/10.1159/000441775 Text en Copyright © 2015 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Published online: October 2015
Carter, Corey A.
Degesys, Aiste
Oronsky, Bryan
Scicinski, Jan
Caroen, Scott Z.
Oronsky, Arnold L.
Reid, Tony
Cabrales, Pedro
Roswarski, Joe
Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor
title Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor
title_full Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor
title_fullStr Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor
title_full_unstemmed Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor
title_short Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor
title_sort flushing out carcinoid syndrome: beneficial effect of the anticancer epigenetic agent rrx-001 in a patient with a treatment-refractory neuroendocrine tumor
topic Published online: October 2015
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649750/
https://www.ncbi.nlm.nih.gov/pubmed/26600780
http://dx.doi.org/10.1159/000441775
work_keys_str_mv AT cartercoreya flushingoutcarcinoidsyndromebeneficialeffectoftheanticancerepigeneticagentrrx001inapatientwithatreatmentrefractoryneuroendocrinetumor
AT degesysaiste flushingoutcarcinoidsyndromebeneficialeffectoftheanticancerepigeneticagentrrx001inapatientwithatreatmentrefractoryneuroendocrinetumor
AT oronskybryan flushingoutcarcinoidsyndromebeneficialeffectoftheanticancerepigeneticagentrrx001inapatientwithatreatmentrefractoryneuroendocrinetumor
AT scicinskijan flushingoutcarcinoidsyndromebeneficialeffectoftheanticancerepigeneticagentrrx001inapatientwithatreatmentrefractoryneuroendocrinetumor
AT caroenscottz flushingoutcarcinoidsyndromebeneficialeffectoftheanticancerepigeneticagentrrx001inapatientwithatreatmentrefractoryneuroendocrinetumor
AT oronskyarnoldl flushingoutcarcinoidsyndromebeneficialeffectoftheanticancerepigeneticagentrrx001inapatientwithatreatmentrefractoryneuroendocrinetumor
AT reidtony flushingoutcarcinoidsyndromebeneficialeffectoftheanticancerepigeneticagentrrx001inapatientwithatreatmentrefractoryneuroendocrinetumor
AT cabralespedro flushingoutcarcinoidsyndromebeneficialeffectoftheanticancerepigeneticagentrrx001inapatientwithatreatmentrefractoryneuroendocrinetumor
AT roswarskijoe flushingoutcarcinoidsyndromebeneficialeffectoftheanticancerepigeneticagentrrx001inapatientwithatreatmentrefractoryneuroendocrinetumor

Ejemplares similares